NCAPH drives breast cancer progression and identifies a gene signature that predicts luminal a tumour recurrence.
Marina Mendiburu-EliçabeNatalia García-SanchaRoberto Corchado-CobosAngélica Martínez-LópezHang ChangJian-Hua MaoAdrián Blanco-GómezAna García-CasasAndrés Castellanos-MartínNélida SalvadorAlejandro Jiménez-NavasManuel Jesús Pérez-BaenaManuel Adolfo Sánchez-MartínMaría Del Mar Abad-HernándezSofía Del CarmenJuncal Claros-AmpueroJuan Jesús Cruz-HernándezCésar Augusto Rodríguez-SánchezMaría Begoña García-CenadorFrancisco Javier García-CriadoRodrigo Santamaría VicenteSonia Castillo-LluvaJesús Pérez LosadaPublished in: Clinical and translational medicine (2024)
The GSLA10 signature outperformed the Oncotype DX signature in discerning tumours with unfavourable outcomes, previously categorised as luminal A by Prediction Analysis of Microarray 50 (PAM50) across three independent human cohorts. This new signature holds promise for identifying luminal A tumour patients with adverse prognosis, aiding in the development of personalised treatment strategies to significantly improve patient outcomes.